<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Intractable Rare Dis Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Intractable Rare Dis Res</journal-id>
<journal-id journal-id-type="publisher-id">irdr</journal-id>
<journal-id journal-id-type="hwp">irdr</journal-id>
<journal-title-group>
<journal-title>Intractable &amp; Rare Diseases Research</journal-title>
</journal-title-group>
<issn pub-type="ppub">2186-3644</issn>
<issn pub-type="epub">2186-361X</issn>
<publisher>
<publisher-name>International Research and Cooperation Association for Bio &amp; Socio-Sciences Advancement</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27672537</article-id>
<article-id pub-id-type="pmc">4995426</article-id>
<article-id pub-id-type="doi">10.5582/irdr.2016.01048</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Fragile X syndrome: A review of clinical management</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lozano</surname>
<given-names>Reymundo</given-names>
</name>
<xref ref-type="aff" rid="a1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="a2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Azarang</surname>
<given-names>Atoosa</given-names>
</name>
<xref ref-type="aff" rid="a1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="a2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wilaisakditipakorn</surname>
<given-names>Tanaporn</given-names>
</name>
<xref ref-type="aff" rid="a1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="a2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hagerman</surname>
<given-names>Randi J</given-names>
</name>
<xref ref-type="aff" rid="a1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="a2">
<sup>2</sup>
</xref>
</contrib>
<aff id="a1"><label>1</label> Medical Investigation of Neurodevelopmental Disorders MIND Institute, UC Davis, CA, USA</aff>
<aff id="a2"><label>2</label> Department of Pediatrics, UC Davis, Sacramento, CA, USA</aff>
</contrib-group>
<author-notes>
<corresp id="c1"><label>*</label><italic>Address correspondence to:</italic> Dr. Reymundo Lozano, Medical Investigation of Neurodevelopmental Disorders MIND Institute, UC Davis, CA, USA; Department of Pediatrics, UC Davis, Sacramento, CA, USA. E-mail: <email>Reymundo.lozano@mssm.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>8</month>
<year>2016</year>
</pub-date>
<volume>5</volume>
<issue>3</issue>
<fpage>145</fpage>
<lpage>157</lpage>
<history>
<date date-type="received">
<day>17</day>
<month>6</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>29</day>
<month>6</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>4</day>
<month>7</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>2016, International Research and Cooperation Association for Bio &amp; Socio-Sciences Advancement</copyright-statement>
<copyright-year>2016</copyright-year>
</permissions>
<abstract>
<title>Summary</title>
<p>The fragile X mental retardation 1 gene, which codes for the fragile X mental retardation 1 protein, usually has 5 to 40 CGG repeats in the 5â€² untranslated promoter. The full mutation is the almost always the cause of fragile X syndrome (FXS). The prevalence of FXS is about 1 in 4,000 to 1 in 7,000 in the general population although the prevalence varies in different regions of the world. FXS is the most common inherited cause of intellectual disability and autism. The understanding of the neurobiology of FXS has led to many targeted treatments, but none have cured this disorder. The treatment of the medical problems and associated behaviors remain the most useful intervention for children with FXS. In this review, we focus on the non-pharmacological and pharmacological management of medical and behavioral problems associated with FXS as well as current recommendations for follow-up and surveillance.</p>
</abstract>
<kwd-group kwd-group-type="author">
<kwd>Fragile X syndrome</kwd>
<kwd>Autism Spectrum Disorder</kwd>
<kwd>Intellectual Disability</kwd>
<kwd>developmental delay</kwd>
<kwd>premutation</kwd>
<kwd>clinical management</kwd>
<kwd>clinical guidelines</kwd>
<kwd>treatment</kwd>
<kwd>medical problems</kwd>
<kwd>
<italic>FMR1</italic>
</kwd>
<kwd>FMRP</kwd>
</kwd-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="1"></table-count>
<ref-count count="150"></ref-count>
<page-count count="13"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>